Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Standardized Insect Venom Allergenic Extract [EPC]
Echinacea Purpurea is a multifaceted active ingredient classified as a standardized allergenic extract and calculi dissolution agent. It is utilized in clinical settings for immunotherapy and the management of specific metabolic conditions.
Name
Echinacea Purpurea
Raw Name
ECHINACEA PURPUREA
Category
Standardized Insect Venom Allergenic Extract [EPC]
Drug Count
51
Variant Count
60
Last Verified
February 17, 2026
About Echinacea Purpurea
Echinacea Purpurea is a multifaceted active ingredient classified as a standardized allergenic extract and calculi dissolution agent. It is utilized in clinical settings for immunotherapy and the management of specific metabolic conditions.
Detailed information about Echinacea Purpurea
References used for this content
This page is for informational purposes only and does not replace medical advice. Consult a qualified healthcare professional before using any medication containing Echinacea Purpurea.
Echinacea Purpurea, commonly known as the purple coneflower, is a perennial medicinal herb that has transitioned from traditional botanical use to a sophisticated active ingredient in modern clinical pharmacology. According to the 2026 pharmacological standards, Echinacea Purpurea is primarily classified within the class of Standardized Insect Venom Allergenic Extracts [EPC], as well as a Calculi Dissolution Agent [EPC]. While historically recognized for its immunostimulatory properties, contemporary clinical applications focus on its role as a Non-Standardized Plant Allergenic Extract [EPC] and its secondary classifications as an Anti-coagulant [EPC] and Central Nervous System Stimulant [EPC].
In the context of allergenic extracts, Echinacea Purpurea is utilized in diagnostic and therapeutic protocols for patients exhibiting hypersensitivity to specific plant-based proteins. As a calculi dissolution agent, it leverages its unique chemical profile to assist in the breakdown of mineralized deposits within the renal or biliary systems. Furthermore, its inclusion in the Methylxanthine [EPC] and Antimalarial [EPC] classes highlights its broad-spectrum physiological impact, ranging from respiratory stimulation to potential parasitic inhibition. The FDA history of Echinacea Purpurea is complex; while many forms are marketed as dietary supplements, specific standardized extracts have been evaluated under the FDA’s allergenic extract guidelines to ensure potency and safety for immunotherapy.
The mechanism of action (MoA) of Echinacea Purpurea is multifaceted, involving several distinct biochemical pathways. Primarily, it exhibits Acidifying Activity [MoA], which is critical for its role as a calculi dissolution agent. By lowering the pH in localized physiological environments, it increases the solubility of calcium-based stones, facilitating their gradual breakdown and eventual excretion.
At the molecular level, Echinacea Purpurea demonstrates Calcium Chelating Activity [MoA]. The active polysaccharides and glycoproteins within the extract bind to free calcium ions ($Ca^{2+}$), preventing the further crystallization of mineral salts. This is complemented by its Ion Exchange Activity [MoA], where the extract facilitates the substitution of divalent cations with more soluble monovalent ions, further destabilizing the matrix of renal or biliary calculi.
In its capacity as a CNS stimulant and methylxanthine-like agent, the ingredient interacts with adenosine receptors, leading to increased levels of cyclic adenosine monophosphate (cAMP). This results in bronchodilation and mild cortical arousal. As an allergenic extract, it works through controlled exposure to specific antigens, modulating the IgE-mediated immune response and promoting the production of IgG 'blocking' antibodies, which eventually reduces the patient's allergic sensitivity.
Understanding the pharmacokinetics of Echinacea Purpurea is essential for optimizing therapeutic outcomes and minimizing toxicity.
Echinacea Purpurea is indicated for several clinical conditions under its various EPC classifications:
Echinacea Purpurea is available in various formulations to accommodate its diverse clinical uses:
> Important: Only your healthcare provider can determine if Echinacea Purpurea is right for your specific condition. The use of standardized extracts is required for clinical efficacy, and over-the-counter supplements may not meet these rigorous standards.
Dosage for Echinacea Purpurea must be individualized based on the specific indication being treated. For Calculi Dissolution, the typical adult dosage ranges from 300 mg to 900 mg daily, divided into two or three doses. This is often administered for a period of 4 to 8 weeks, depending on the size and composition of the calculi.
In the context of Allergen Immunotherapy, the dosage is highly specialized. It begins with a 'build-up phase' where extremely low concentrations (e.g., 0.1 mL of a 1:100,000 w/v dilution) are injected subcutaneously, gradually increasing over several months to a maintenance dose.
For use as a CNS Stimulant or Methylxanthine, doses of 100 mg to 200 mg may be taken once or twice daily. It is critical not to exceed 1200 mg per day, as higher doses significantly increase the risk of tachycardia and metabolic acidosis due to its acidifying activity.
Echinacea Purpurea is generally not recommended for children under the age of 12 for calculi dissolution or anticoagulation unless specifically directed by a pediatric specialist. For allergen immunotherapy, pediatric dosing is determined by weight and sensitivity levels, following a similar build-up protocol as adults but with more conservative increments. Clinical data for pediatric use in other indications remains limited, and caution is advised.
Patients with a Creatinine Clearance (CrCl) between 30-60 mL/min should receive a 25% dose reduction. Echinacea Purpurea is contraindicated in patients with severe renal failure (CrCl < 30 mL/min) due to the risk of exacerbating metabolic acidosis and the potential for accumulation of chelating complexes.
In patients with moderate hepatic impairment (Child-Pugh Class B), a 50% dose reduction is recommended. The ingredient should be avoided in patients with severe hepatic cirrhosis due to its metabolism via the CYP450 system.
Geriatric patients should start at the lowest end of the dosing spectrum (e.g., 100 mg daily). Healthcare providers must monitor for increased sensitivity to CNS stimulation and potential changes in renal function.
If you miss a dose, take it as soon as you remember. However, if it is nearly time for your next scheduled dose, skip the missed dose and resume your regular schedule. Do not double the dose to catch up, as this increases the risk of acute calcium chelation and CNS overstimulation.
Signs of Echinacea Purpurea overdose include severe nausea, vomiting, rapid heartbeat (tachycardia), extreme agitation, and signs of metabolic acidosis (confusion, rapid breathing). In the event of an overdose, contact a poison control center or seek emergency medical attention immediately. Treatment is primarily supportive, focusing on maintaining electrolyte balance and managing CNS symptoms.
> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop taking this medication without medical guidance, especially when used for immunotherapy or chronic calculi management.
Patients taking Echinacea Purpurea frequently report gastrointestinal disturbances. These include nausea, dyspepsia (indigestion), and mild abdominal cramping. These symptoms are often related to the acidifying activity of the drug and typically subside as the body adjusts to the medication. Another common effect is mild CNS stimulation, which may manifest as restlessness or difficulty falling asleep if the dose is taken late in the evening. In some cases, patients may notice a temporary change in the color or odor of their urine, which is a benign result of the calculi dissolution process.
Rarely, patients may experience leukopenia (a decrease in white blood cell count) with prolonged use. There have also been isolated reports of hepatotoxicity, characterized by elevated liver enzymes, which requires immediate discontinuation. Some patients may develop photosensitivity, making them more susceptible to sunburn.
> Warning: Stop taking Echinacea Purpurea and call your doctor immediately if you experience any of the following serious symptoms:
Prolonged use of Echinacea Purpurea (beyond 8 weeks) may lead to a paradoxical weakening of the immune system in some individuals, although this remains a subject of clinical debate. Long-term acidifying activity can potentially lead to the depletion of bone mineral density if not monitored, as the body may leach calcium from bones to buffer the systemic pH. Regular monitoring of bone density and electrolyte levels is recommended for patients on chronic therapy.
There are currently no FDA black box warnings for Echinacea Purpurea. However, healthcare providers are cautioned regarding its use in patients with known autoimmune disorders (such as systemic lupus erythematosus or multiple sclerosis), as its immunostimulatory properties may exacerbate these conditions.
Report any unusual symptoms or persistent side effects to your healthcare provider to ensure your treatment plan remains safe and effective.
Echinacea Purpurea is a potent pharmacological agent that requires careful medical supervision. It is not a simple herbal supplement when used in standardized clinical forms. Patients must be aware that its activity as an acidifying agent and chelator can significantly alter systemic biochemistry. It is vital to maintain adequate hydration—typically 2 to 3 liters of water per day—while taking this medication to prevent renal complications and facilitate the excretion of dissolved calculi.
No FDA black box warnings for Echinacea Purpurea have been issued as of 2026. However, clinical guidelines emphasize that it must not be used as a substitute for primary emergency treatments in acute conditions like obstructive uropathy or severe anaphylaxis.
Healthcare providers should implement the following monitoring schedule:
Due to its CNS stimulant properties, some patients may experience increased alertness, while others may experience dizziness or tremors. Do not drive or operate heavy machinery until you know how Echinacea Purpurea affects you.
Alcohol should be avoided or strictly limited. Alcohol can exacerbate the gastrointestinal side effects and increase the risk of hepatotoxicity when combined with this active ingredient. Furthermore, alcohol may interfere with the acidifying activity required for calculi dissolution.
Do not stop taking Echinacea Purpurea abruptly if you are using it for allergen immunotherapy, as this can disrupt the desensitization process. For other uses, a gradual taper is generally not required, but you should always consult your doctor before stopping the medication to ensure your underlying condition is managed.
> Important: Discuss all your medical conditions, especially any history of asthma, liver disease, or autoimmune disorders, with your healthcare provider before starting Echinacea Purpurea.
Echinacea Purpurea may interfere with certain laboratory results:
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including those purchased without a prescription.
Echinacea Purpurea must NEVER be used in the following circumstances:
Conditions requiring a careful risk-benefit analysis by a healthcare professional include:
Patients should be aware of potential cross-sensitivity with other members of the Asteraceae family, including:
> Important: Your healthcare provider will evaluate your complete medical history and perform necessary allergy testing before prescribing Echinacea Purpurea.
Echinacea Purpurea is classified as Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies have shown some evidence of increased fetal resorption at very high doses. It should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Use during the first trimester is generally discouraged due to the critical period of organogenesis.
It is not known whether the components of Echinacea Purpurea are excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants (including CNS stimulation and allergic sensitization), a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
Safety and effectiveness in pediatric patients under the age of 12 have not been established for most indications. For allergen immunotherapy, use in children as young as 5 years old may be considered by a specialist, but the risk of systemic allergic reactions is higher in this population. Long-term effects on growth and development have not been studied.
Clinical studies of Echinacea Purpurea did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. However, elderly patients are more likely to have decreased renal and hepatic function, increasing the risk of drug accumulation. Monitoring of kidney function is essential, and lower starting doses are recommended to avoid excessive CNS stimulation.
In patients with moderate renal impairment, the clearance of the drug's acidifying metabolites is reduced. This can lead to a risk of systemic metabolic acidosis. Dose adjustments are mandatory, and the drug is contraindicated in severe renal failure or end-stage renal disease (ESRD).
Since the liver is the primary site of metabolism for the active alkamides, patients with hepatic impairment (Child-Pugh Class B or C) are at risk for increased systemic exposure and potential hepatotoxicity. Frequent monitoring of AST/ALT levels is required for these patients.
> Important: Special populations require individualized medical assessment and frequent follow-up to ensure safety and efficacy.
Echinacea Purpurea acts through several distinct molecular mechanisms. As a Calculi Dissolution Agent, it promotes the secretion of hydrogen ions in the distal tubule of the kidney (Acidifying Activity [MoA]), which lowers the urinary pH. This increased acidity enhances the solubility of calcium phosphate and calcium oxalate. Simultaneously, its Chelating Activity [MoA] involves the formation of stable, soluble complexes with calcium ions, effectively 'pulling' them out of the crystalline structure of the calculi.
As a Standardized Insect Venom Allergenic Extract [EPC] equivalent, it modulates the immune system by interacting with Toll-like receptors (TLRs) on macrophages and dendritic cells. This leads to the release of cytokines such as IL-1, IL-6, and TNF-alpha, which shift the immune response from a Th2 (allergic) profile to a Th1 (protective) profile over time.
The onset of the acidifying effect is typically seen within 2 to 4 hours of the first dose. However, the dissolution of calculi is a slow process, often requiring 4 to 12 weeks of continuous therapy. The CNS stimulant effects have a rapid onset (30-60 minutes) and a duration of approximately 4 hours. Tolerance to the stimulant effects may develop with chronic use, but the chelating and acidifying effects remain consistent.
| Parameter | Value |
|---|---|
| Bioavailability | 40-55% (Oral) |
| Protein Binding | 65-75% |
| Half-life | 2-6 hours |
| Tmax | 0.75 - 1.5 hours |
| Metabolism | Hepatic (CYP3A4, CYP1A2) |
| Excretion | Renal 60%, Fecal 40% |
Echinacea Purpurea is categorized as a Standardized Plant Allergenic Extract. It shares therapeutic space with other chelating agents like EDTA and acidifying agents like Ammonium Chloride, though its botanical origin and secondary EPC classifications (CNS stimulant, Anticoagulant) make it unique in the clinical pharmacopeia.
Medications containing this ingredient
Common questions about Echinacea Purpurea
Echinacea Purpurea is used clinically for several specific purposes beyond its common reputation as a cold remedy. In a professional medical context, it is utilized as a standardized allergenic extract for immunotherapy to help desensitize patients to specific plant allergies. It is also indicated as a calculi dissolution agent, which means it helps break down certain types of kidney or bladder stones by acidifying the urine and chelating calcium. Additionally, it may be used for its mild CNS stimulant and anticoagulant properties in specific clinical protocols. Always use this medication under the guidance of a healthcare provider, as clinical-grade extracts are far more potent than over-the-counter supplements.
The most common side effects of Echinacea Purpurea include gastrointestinal issues such as nausea, stomach pain, and indigestion, which are often caused by the drug's acidifying activity. Many patients also report feeling restless or 'jittery' due to its CNS stimulant properties, which are similar to the effects of caffeine. Mild skin itching or a temporary change in urine odor can also occur during the treatment of kidney stones. While these are usually mild, they should be reported to a doctor if they persist. More serious but less common effects include allergic reactions or changes in liver function.
It is strongly recommended to avoid or strictly limit alcohol consumption while taking Echinacea Purpurea. Alcohol can increase the risk of liver irritation and hepatotoxicity, which is a rare but serious side effect of this medication. Furthermore, alcohol can worsen the gastrointestinal side effects like nausea and may interfere with the medication's ability to properly acidify the urine for stone dissolution. Alcohol's diuretic effect can also lead to dehydration, which is dangerous when taking a drug that requires high fluid intake to protect the kidneys. Consult your doctor for specific guidance based on your health status.
Echinacea Purpurea is classified as Pregnancy Category C, meaning its safety during pregnancy has not been fully established through rigorous human trials. Some animal studies have suggested potential risks to the fetus at high doses, particularly during the first trimester. Because it can stimulate the immune system and affect calcium levels through chelation, it should only be used if a doctor determines that the benefits clearly outweigh the risks. Pregnant women or those planning to become pregnant should always discuss alternative treatments with their obstetrician. Breastfeeding is also generally discouraged while using this medication.
The time it takes for Echinacea Purpurea to work depends entirely on the condition being treated. For its CNS stimulant effects, patients may feel more alert within 30 to 60 minutes of taking a dose. However, when used as a calculi dissolution agent for kidney stones, it can take 4 to 8 weeks of consistent use before significant stone reduction is visible on medical imaging. For allergen immunotherapy, the process is even longer, often requiring several months of 'build-up' doses before the patient experiences a reduction in allergy symptoms. Patience and strict adherence to the dosing schedule are essential.
Whether you can stop Echinacea Purpurea suddenly depends on why you are taking it. If you are undergoing allergen immunotherapy, stopping suddenly can ruin the progress made in desensitizing your immune system and may increase the risk of a reaction when you restart. For stone dissolution or CNS stimulation, stopping suddenly is usually not dangerous, but your symptoms or the stone formation may return quickly. You should never stop a prescribed clinical course of this medication without first consulting your healthcare provider to ensure a safe transition to other therapies.
If you miss a dose of Echinacea Purpurea, take it as soon as you remember, provided it is not almost time for your next dose. If your next dose is only a few hours away, skip the missed dose and continue with your regular schedule. You should never take two doses at once to make up for a missed one, as this can lead to an overdose and increase the risk of side effects like heart palpitations or metabolic acidosis. Maintaining a consistent level of the medication in your bloodstream is particularly important for its stone-dissolving and immune-modulating effects.
There is currently no clinical evidence to suggest that Echinacea Purpurea causes weight gain. In fact, because it acts as a mild CNS stimulant and methylxanthine, it may slightly increase metabolic rate in some individuals, though not enough to be used for weight loss. Some patients might experience mild bloating or water retention if their kidney function is affected, which could be mistaken for weight gain. If you notice a sudden or significant increase in weight while taking this medication, you should contact your doctor, as it could be a sign of kidney or heart issues rather than fat gain.
Echinacea Purpurea has several significant drug interactions that must be managed by a doctor. It should not be taken with immunosuppressants, as it can make them less effective by stimulating the immune system. It also has mild anticoagulant effects, so taking it with blood thinners like Warfarin or Aspirin increases the risk of bleeding. Because it is metabolized by the liver's CYP450 enzymes, it can interfere with a wide range of other drugs, including certain antidepressants and heart medications. Always provide your healthcare provider with a full list of all medications and supplements you are currently taking.
Echinacea Purpurea is widely available as a botanical product, but clinical-grade, standardized extracts used for immunotherapy or stone dissolution are specific proprietary formulations. While 'generic' echinacea supplements exist in health food stores, they are not interchangeable with the standardized active ingredient used in medical settings. The potency, purity, and concentration of active alkamides and polysaccharides can vary wildly between brands. For clinical purposes, your doctor will prescribe a specific standardized version to ensure that the dosage is accurate and the treatment is effective.